• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

获取新冠疫苗:一种新的全球方法。

Access to COVID-19 Vaccines: A New Global Approach.

作者信息

Bouderhem Rabaï

机构信息

College of Law, Prince Mohammad Bin Fahd University, P.O. Box 1664, Al Khobar 31952, Saudi Arabia.

出版信息

Vaccines (Basel). 2022 Oct 25;10(11):1795. doi: 10.3390/vaccines10111795.

DOI:10.3390/vaccines10111795
PMID:36366304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9694144/
Abstract

This paper addresses the legal aspects and unprecedented consequences of the Coronavirus disease 2019 (COVID-19) pandemic on the manufacturing and fair access to vaccines. A research literature review allowed us to identify and evaluate the weaknesses of international health law to combat global health crises such as the COVID-19 pandemic. A new paradigm must encourage World Health Organization (WHO) and World Trade Organization (WTO) members to explicitly consider vaccines as global public goods and adopt a new set of legally binding rules for a fair and unrestricted access in times of pandemic. Initiatives and mechanisms such as COVID-19 Vaccine Global Access Facility (COVAX) have been developed to tackle the pandemic and allow developing countries to access vaccines but most were limited and never reached the expected results. The key role played by the WHO in global health policy needs to be strengthened throughout the revision of the International Health Regulations (IHR). Globalization and health are interconnected: WTO members shall revise the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) and grant permanent intellectual property (IP) waivers on vaccines in times of pandemic. Our postulation is that vaccines constitute global public goods; their manufacturing and access must be facilitated and guaranteed by specific rules and mechanisms under the supervision of both the WHO and the WTO. It is, therefore, essential to provide the WHO with new powers and attributions to impose coordinated health policies to combat diseases and global crises such as the COVID-19 pandemic.

摘要

本文探讨了2019年冠状病毒病(COVID-19)大流行对疫苗生产和公平获取所带来的法律问题及前所未有的后果。通过对研究文献的综述,我们得以识别和评估国际卫生法在应对诸如COVID-19大流行等全球卫生危机方面的弱点。一种新的范式必须鼓励世界卫生组织(WHO)和世界贸易组织(WTO)的成员国明确将疫苗视为全球公共产品,并采用一套新的具有法律约束力的规则,以便在大流行期间实现公平且不受限制的获取。诸如COVID-19疫苗全球获取机制(COVAX)等倡议和机制已被制定出来以应对大流行,并使发展中国家能够获取疫苗,但大多数举措都很有限,从未达到预期效果。在修订《国际卫生条例》(IHR)的整个过程中,需要加强WHO在全球卫生政策中所发挥的关键作用。全球化与健康相互关联:WTO成员国应修订《与贸易有关的知识产权协定》(TRIPS协定),并在大流行期间给予疫苗永久性知识产权豁免。我们的假设是,疫苗构成全球公共产品;其生产和获取必须由WHO和WTO监督下的特定规则和机制来促进和保障。因此,至关重要的是赋予WHO新的权力和职责,以实施协调一致的卫生政策来抗击疾病和诸如COVID-19大流行等全球危机。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ec/9694144/5e1ba2413c32/vaccines-10-01795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ec/9694144/5e1ba2413c32/vaccines-10-01795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ec/9694144/5e1ba2413c32/vaccines-10-01795-g001.jpg

相似文献

1
Access to COVID-19 Vaccines: A New Global Approach.获取新冠疫苗:一种新的全球方法。
Vaccines (Basel). 2022 Oct 25;10(11):1795. doi: 10.3390/vaccines10111795.
2
Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.与贸易有关的知识产权方面的灵活性和公共卫生:将强制许可条款纳入国家专利立法。
Milbank Q. 2023 Dec;101(4):1280-1303. doi: 10.1111/1468-0009.12669. Epub 2023 Aug 30.
3
Intellectual Property and the Politics of Public Good during COVID-19: Framing Law, Institutions, and Ideas during TRIPS Waiver Negotiations at the WTO.新冠疫情期间的知识产权与公益政治:WTO 豁免 TRIPS 谈判中的法律、制度和理念框架。
J Health Polit Policy Law. 2024 Feb 1;49(1):9-42. doi: 10.1215/03616878-10910269.
4
The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.满足全球公共卫生需求的流行性和大流行性疫苗的未来。
Vaccines (Basel). 2023 Mar 17;11(3):690. doi: 10.3390/vaccines11030690.
5
Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders.**提高 COVID-19 疫苗可及性:对 WTO 成员、民间社会组织和制药行业利益相关者中 TRIPS 豁免讨论的分析**。
Health Hum Rights. 2022 Dec;24(2):159-175.
6
International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.国际合作确保公平获取 COVID-19 疫苗:ACT-Accelerator 和 COVAX 设施。
Milbank Q. 2021 Jun;99(2):426-449. doi: 10.1111/1468-0009.12503. Epub 2021 Mar 2.
7
COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.COVID-19 疫苗、TRIPS 协定与全球卫生外交:印度在世贸组织平台上的作用。
Biomed Res Int. 2021 Aug 26;2021:6658070. doi: 10.1155/2021/6658070. eCollection 2021.
8
Managing the effect of TRIPS on availability of priority vaccines.应对《与贸易有关的知识产权协定》对优先疫苗可得性的影响。
Bull World Health Organ. 2006 May;84(5):360-5. doi: 10.2471/blt.05.028431. Epub 2006 May 17.
9
Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.设计全球疫苗供应链:在新冠疫情后平衡知识产权与疫苗公平。
BMJ Glob Health. 2023 Nov 30;8(11):e013669. doi: 10.1136/bmjgh-2023-013669.
10
Does TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) prevent COVID-19 vaccines as a global public good?《与贸易有关的知识产权协定》(TRIPS)是否阻碍了新冠疫苗成为全球公共产品?
J World Intellect Prop. 2021 Jul;24(3-4):195-220. doi: 10.1111/jwip.12187. Epub 2021 Mar 18.

引用本文的文献

1
How Did We Get Here: The Best Vaccines Ever Facing the Highest Public Hesitancy?我们如何走到这一步:史上最佳疫苗却面临着最高的公众犹豫态度?
Vaccines (Basel). 2023 Aug 4;11(8):1323. doi: 10.3390/vaccines11081323.

本文引用的文献

1
Closing the global vaccine equity gap: equitably distributed manufacturing.缩小全球疫苗公平差距:公平分配生产
Lancet. 2022 May 21;399(10339):1924-1926. doi: 10.1016/S0140-6736(22)00793-0. Epub 2022 May 6.
2
Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good.应对疫苗不平等——将新冠疫苗视为全球公共产品
N Engl J Med. 2022 Mar 24;386(12):1176-1179. doi: 10.1056/NEJMe2202547. Epub 2022 Feb 23.
3
Addressing production gaps for vaccines in African countries.解决非洲国家疫苗生产缺口问题。
Bull World Health Organ. 2021 Dec 1;99(12):910-912. doi: 10.2471/BLT.21.287381. Epub 2021 Nov 17.
4
Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries.全球获取 COVID-19 疫苗:可能影响中低收入国家公平获取疫苗的因素的范围综述。
BMJ Open. 2021 Sep 30;11(9):e049505. doi: 10.1136/bmjopen-2021-049505.
5
The fight to manufacture COVID vaccines in lower-income countries.在低收入国家生产新冠疫苗的斗争。
Nature. 2021 Sep;597(7877):455-457. doi: 10.1038/d41586-021-02383-z.
6
COVID-19 vaccines a global public good? Moving past the rhetoric and making work of sharing intellectual property rights, know-how and technology.新冠疫苗是全球公共产品?摒弃空谈,推动知识产权、专有技术和技术共享工作。
Eur J Public Health. 2021 Oct 26;31(5):925-926. doi: 10.1093/eurpub/ckab144.
7
COVID vaccines to reach poorest countries in 2023 - despite recent pledges.尽管近期有承诺,但新冠疫苗要到2023年才能抵达最贫穷国家。
Nature. 2021 Jul;595(7867):342-343. doi: 10.1038/d41586-021-01762-w.
8
Should COVID-19 Vaccines Authorized for Emergency Use Be Considered "Essential" Medicines?新冠病毒疫苗在紧急使用授权下应被视为“基本”药物吗?
Health Hum Rights. 2021 Jun;23(1):145-150.
9
A beautiful idea: how COVAX has fallen short.一个美好的设想:新冠疫苗全球获取机制(COVAX)为何未达预期。
Lancet. 2021 Jun 19;397(10292):2322-2325. doi: 10.1016/S0140-6736(21)01367-2.
10
Can we do for other essential medicines what we are doing for the COVID-19 vaccine?我们能否像为新冠疫苗所做的那样,为其他基本药物做同样的事?
BMJ Glob Health. 2021 Feb;6(2). doi: 10.1136/bmjgh-2021-005158.